Abstract
elbion (formerly ASTA Medica) and GlaxoSmithKline are developing an inhaled formulation of AWD-12-281 for the potential treatment of chronic obstructive pulmonary disease (COPD). By May 2005, phase II trials of this 5-hydroxyindole PDE4 inhibitor for COPD were ongoing.
MeSH terms
-
3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors*
-
Administration, Inhalation
-
Administration, Topical
-
Amides / administration & dosage
-
Amides / pharmacokinetics
-
Amides / therapeutic use*
-
Aminopyridines / chemistry
-
Animals
-
Benzamides / chemistry
-
Clinical Trials as Topic
-
Cyclic Nucleotide Phosphodiesterases, Type 4
-
Cyclopropanes / chemistry
-
Dermatitis, Atopic / drug therapy*
-
Disease Models, Animal
-
Drug Evaluation, Preclinical
-
Humans
-
Indoles / administration & dosage
-
Indoles / pharmacokinetics
-
Indoles / therapeutic use*
-
Inflammation / chemically induced
-
Inflammation / drug therapy
-
Lipopolysaccharides
-
Ovalbumin
-
Phosphodiesterase Inhibitors / administration & dosage
-
Phosphodiesterase Inhibitors / pharmacokinetics
-
Phosphodiesterase Inhibitors / therapeutic use*
-
Psoriasis / drug therapy*
-
Pulmonary Disease, Chronic Obstructive / drug therapy*
-
Respiratory Tract Diseases / chemically induced
-
Respiratory Tract Diseases / drug therapy
-
Structure-Activity Relationship
Substances
-
AWD 12-281
-
Amides
-
Aminopyridines
-
Benzamides
-
Cyclopropanes
-
Indoles
-
Lipopolysaccharides
-
Phosphodiesterase Inhibitors
-
Roflumilast
-
Ovalbumin
-
3',5'-Cyclic-AMP Phosphodiesterases
-
Cyclic Nucleotide Phosphodiesterases, Type 4